BidaskClub upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a hold rating to a buy rating in a report published on Saturday.

NTLA has been the topic of a number of other reports. ValuEngine upgraded shares of Intellia Therapeutics from a hold rating to a buy rating in a report on Saturday, June 2nd. Wedbush restated an outperform rating and issued a $36.00 target price on shares of Intellia Therapeutics in a report on Friday, May 18th. Chardan Capital restated a buy rating and issued a $57.50 target price on shares of Intellia Therapeutics in a report on Friday, August 24th. Finally, Zacks Investment Research downgraded shares of Intellia Therapeutics from a buy rating to a hold rating in a report on Tuesday, August 7th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Intellia Therapeutics currently has an average rating of Buy and an average price target of $39.50.

Shares of NASDAQ NTLA opened at $31.05 on Friday. Intellia Therapeutics has a 52-week low of $16.33 and a 52-week high of $35.99. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -16.52 and a beta of 3.09.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Wednesday, August 1st. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03. Intellia Therapeutics had a negative net margin of 284.56% and a negative return on equity of 31.54%. The firm had revenue of $7.68 million for the quarter, compared to the consensus estimate of $6.39 million. During the same period in the previous year, the firm posted ($0.45) EPS. The business’s quarterly revenue was up 30.2% on a year-over-year basis. equities research analysts predict that Intellia Therapeutics will post -1.97 earnings per share for the current year.

In other news, Director Jean Francois Formela sold 6,686 shares of the business’s stock in a transaction dated Monday, July 16th. The shares were sold at an average price of $31.17, for a total value of $208,402.62. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 12.80% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Legal & General Group Plc grew its holdings in Intellia Therapeutics by 75.4% during the 2nd quarter. Legal & General Group Plc now owns 5,427 shares of the company’s stock valued at $149,000 after purchasing an additional 2,333 shares during the last quarter. D.A. Davidson & CO. grew its holdings in Intellia Therapeutics by 14.2% during the 1st quarter. D.A. Davidson & CO. now owns 19,219 shares of the company’s stock valued at $405,000 after purchasing an additional 2,395 shares during the last quarter. Great West Life Assurance Co. Can grew its holdings in Intellia Therapeutics by 2.5% during the 2nd quarter. Great West Life Assurance Co. Can now owns 97,031 shares of the company’s stock valued at $2,652,000 after purchasing an additional 2,395 shares during the last quarter. TRUE Private Wealth Advisors grew its holdings in Intellia Therapeutics by 23.5% during the 2nd quarter. TRUE Private Wealth Advisors now owns 13,296 shares of the company’s stock valued at $363,000 after purchasing an additional 2,533 shares during the last quarter. Finally, New York State Common Retirement Fund grew its holdings in Intellia Therapeutics by 12.8% during the 1st quarter. New York State Common Retirement Fund now owns 25,990 shares of the company’s stock valued at $548,000 after purchasing an additional 2,950 shares during the last quarter. Institutional investors own 66.52% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

See Also: What is a Leveraged Buyout (LBO)?

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.